胸腺肽联合抗结核药物用于老年性肺结核病患者临床治疗的效果分析

Clinical effect analysis of thymosin combined with anti-tuberculosis drugs on elderly patients with pulmonary tuberculosis

目的:探讨胸腺肽联合抗结核药物用于老年性肺结核病患者临床治疗的效果分析。方法:将2016年1月-2017年1月在我院感染科治疗的104例老年性肺结核病患者随机分为两组,对照组采用常规抗结核治疗,观察组采用胸腺肽联合抗结核药物,并辅助金水宝胶囊治疗,比较两组患者的临床疗效、免疫功能、空洞闭合情况。结果:观察组治疗总有效率为96.15%,明显高于对照组的75%,两组间差异有统计学意义(P<0.05);观察组治疗后痰菌转阴率为90.38%,明显高于对照组的73.08%,两组间差异有统计学意义(P<0.05);观察组治疗后空洞闭合有效率明显高于对照组,两组间差异有统计学意义(P<0.05)。结论:胸腺肽联合抗结核药物用于老年性肺结核病患者临床治疗效果良好,利于病灶吸收及空洞闭合,改善机体免疫功能,具有积极的临床意义。

Objective： To explore the effect analysis of thymosin combined with anti-tuberculosis drugs on elderly patients with pulmonary tuberculosis. Methods： 104 elderly patients with pulmonary tuberculosis treated in the infection department of our hospital from January 2016 to January 2017 were randomly divided into two groups. The control group received conventional anti-tuberculosis treatment; while the observation group was treated with thymosin combined with anti-tuberculosis drugs, and assisted with Jinshuibao Capsules. The clinical efficacy, immune function and cavity closure in two groups were compared. Results： The effective rate in the observation group was 96.15%, which was significantly higher than 75.00% in the control group; the difference was statistically significant （P〈0.05）. After treatment, the sputum negative conversion rate in the observation group was 90.38%, which was significantly higher than 73.08% in the control group; the difference was statistically significant （P〈0.05）. After treatment, the effective rate of cavity closure in the observation group was significantly higher than that of the control group （P〈0.05）; the difference between groups was statistically significant （P〈0.05）. Conclusion： Thymosin combined with anti-tuberculosis drugs had a significant effect on elderly patients with pulmonary tuberculosis; it was conducive to the absorption of lesions and cavity closure, could improve the immune function, was of positive clinical significance.